
Topical Drugs CDMO Market Size, Share, Trends & Global Forecast 2026–2035
The Topical Drugs CDMO Market is Segmented By Service Type (Product Development Services, Standalone Analytical and Testing Services, Clinical Manufacturing Services, Commercial Manufacturing Services, Others), By Formulation (Semi-solid Formulations including Creams, Ointments, Gels and Others; Liquid Formulations; Solid Formulations; Transdermal Products), By Product Type (Prescription Drugs, OTC Drugs), By End User (Pharmaceutical Companies, Biopharmaceutical Companies, Others) and Region
Topical Drugs CDMO Market Overview and Definition
The Global Topical Drugs CDMO Market was valued at USD 7.99 Billion in 2025 and is projected to reach USD 16.47 Billion by 2035, growing at a CAGR of 7.50% from 2026 to 2035. Topical drugs contract development and manufacturing organisations (CDMOs) provide specialised services for development, formulation, and commercial production of pharmaceutical products designed for direct application to skin or mucous membranes. Market services span product development, analytical testing, clinical manufacturing, and commercial-scale production serving pharmaceutical and biopharmaceutical companies.
Formulation categories encompass semi-solid preparations including creams, ointments, and gels; liquid formulations; solid formulations; and transdermal delivery systems. Product types address prescription and over-the-counter therapeutic requirements across dermatology, pain management, ophthalmology, and wound care applications. Market growth is driven by escalating outsourcing of topical drug development and manufacturing, increasing complexity of advanced formulations, regulatory compliance requirements, and pharmaceutical industry reliance on specialised CDMO capabilities for product commercialisation.
Key Market Trends & Analysis
- The Global Topical Drugs CDMO Market reached USD 7.99 billion in 2025, reflecting sustained outsourcing of topical pharmaceutical development and manufacturing.
- Forecast market size of USD 16.47 billion by 2035 represents approximately 106% expansion, demonstrating robust demand for specialised CDMO services.
- A CAGR of 7.50% from 2026 to 2035 reflects consistent growth driven by outsourcing trends and formulation complexity expansion.
- Semi-solid formulations dominated with approximately 42.5% market share in 2025, addressing creams, ointments, gels serving dermatology applications.
- Commercial Manufacturing Services represents largest service type, reflecting mature outsourcing market and established manufacturing relationships.
- Prescription Drugs commanded approximately 72% market share in 2025, driven by complex formulation requirements and regulatory compliance needs.
- Pharmaceutical Companies account for approximately 58% end-user segment in 2025, prioritising outsourced manufacturing and development capabilities.
- USA accounts for approximately 79.2% of North American market share, valued at USD 2.44 billion in 2025, projected to reach USD 5.17 billion by 2035.
- In October 2025, MedPharm announced fifth commercial manufacturing agreement in twenty months, strengthening topical product portfolio at Durham facility.
- Europe represents second-largest region with approximately 27.4% global share; Germany held approximately 31% of European market driven by regulatory expertise.
- Asia-Pacific demonstrated strong growth at approximately 24.1% global share and CAGR of 9.8%, driven by pharmaceutical outsourcing expansion.
- In February 2025, Recipharm inaugurated sterile development laboratories at Bengaluru India site, expanding advanced therapy manufacturing capabilities globally.
- In June 2025, Piramal Pharma announced USD 90 million investment across US facilities, expanding sterile injectable and topical manufacturing capacity.
The Topical Drugs CDMO Market includes contract development and manufacturing organizations which provide comprehensive services in relation to pharmaceutical products used on the skin or mucous membrane. Services offered by market players range from product development (covering formulation optimization and regulatory pathway development), analytical and testing services to validate product quality and stability, clinical manufacturing services for regulatory trial purposes, commercial manufacturing services to provide large scale production, and ancillary services including regulatory consultancy and technical transfer.
Formulations include semi-solid forms such as creams (using emulsion system), anhydrous ointments, gels (aqueous or hydroalcoholic) and semi-solid vehicle, liquid forms such as solution, suspension and emulsion, solid forms such as tablets, capsules and powder and transdermal systems such as patches, films and iontophoresis. The product range includes prescription drugs requiring complex development and manufacturing knowhow as well as OTC products for consumer health applications. End users include multinational pharma companies outsourcing their non-core manufacturing requirements, bio-pharmaceutical companies having specialized biologic formulation needs and new biotech companies without manufacturing infrastructure. CDMO competencies include regulatory compliance, quality assurance, batch documentation, supply chain management and technology transfer for product commercialization.
The services of CDMOs for topical drugs provide important infrastructure which helps pharmaceutical companies to fast track product commercialization without the need to make major investments in manufacturing facilities and regulatory compliance infrastructure. Increasing formulation complexity due to advanced delivery systems, novel actives, and regulatory requirements result in continuous demand for specialized CDMO services. Industry consolidation in biopharmaceutical industry and venture capital funding create growing customer base for manufacturing services.
Source: Kaiso Research and Consulting
Regulatory guidelines such as FDA guidance on topical formulations and EMA manufacturing guidelines create compliance issues which require the services of CDMOs. The transition of the pharmaceutical industry from vertically integrated manufacturing model to outsourcing model provides the structure for market growth that will drive the growth of CDMOs. The future outlook predicts further market growth due to growing pipeline for topical drugs, increasing specialization in formulation technologies, the need for manufacturing capabilities in emerging markets and optimization of CDMO network due to geographical and therapeutic specialization. Long term visibility for revenues can be created through strategic partnerships of CDMOs and pharmaceutical companies.
In October 2025, MedPharm signed a commercial manufacturing agreement supporting site transfer and production of a branded specialty topical pharmaceutical product, representing the company's fifth major commercial deal in twenty months, reinforcing market leadership in Durham facility topical expertise.
Recent Developments in the Topical Drugs CDMO Market
- In October 2025, MedPharm, a contract development and manufacturing organisation specialising in topical, transdermal, and transepithelial products, announced a new commercial manufacturing agreement supporting technology transfer and commercial production of a branded specialty topical pharmaceutical product at its Durham, North Carolina facility, representing the fifth commercial deal in twenty months, strengthening portfolio diversification and revenue contribution from technology transfer and 2027 manufacturing revenues.
- In June 2025, Piramal Pharma Solutions announced USD 90 million investment plan to expand two US facilities, including sterile injectable and topical formulation manufacturing capacity at Lexington, Kentucky, and expansion of antibody-drug conjugate payload-linker suite expected operational before 2025 year-end, significantly expanding global sterile pharmaceutical manufacturing capabilities and serving escalating biopharmaceutical outsourcing demand.
- In February 2025, Recipharm inaugurated newly commissioned parenteral development and sterility laboratories at its Bengaluru, India site, expanding CDMO capabilities in sterile pharmaceutical development and analytical testing, enhancing global network for advanced therapy manufacturing and supporting continued double-digit growth projections and strategic capabilities expansion across multiple geographic regions and therapeutic modalities.
- In February 2025, Recipharm announced that its new modular sterile filling system installed in Wasserburg, Germany, achieved full operational status and completed first production run for a leading biotechnology company, expanding capabilities in sterile product manufacturing including antibody-drug conjugates, biologics, and GLP-1 therapeutics, addressing escalating demand for advanced pharmaceutical manufacturing solutions.
- In January 2025, Recipharm and Quebec-based Spektus Pharma announced joint development and supply partnership for novel central nervous system-focused products using Spektus' proprietary Flexitab oral drug delivery platform, creating flexible, breakable extended-release tablets for global markets and demonstrating CDMO commitment to technology partnerships addressing unmet formulation requirements.
Topical Drugs CDMO Market Dynamics: Drivers, Restraints, Opportunities, Challenges and Trends
Drivers: Pharmaceutical outsourcing acceleration and regulatory complexity drive sustained CDMO demand and capacity expansion.
Pharmaceutical companies increasingly prioritise core competencies including drug discovery and commercial operations whilst outsourcing manufacturing and development to specialised CDMOs. Regulatory requirements including FDA guidance for topical formulation development, stability testing protocols, and manufacturing quality standards establish compliance imperatives requiring CDMO expertise. Topical formulation complexity including advanced delivery systems, combination therapies, and specialised semi-solid matrices necessitate specialised CDMO capabilities.
Biopharmaceutical industry growth and venture capital funding create expanding customer bases requiring manufacturing services. Patent cliff dynamics drive generic and biosimilar development creating CDMO demand for manufacturing infrastructure. Pharmaceutical mergers and acquisitions create excess manufacturing capacity driving consolidation and CDMO expansion. Supply chain risk diversification following pandemic disruptions creates demand for geographically distributed CDMO networks. Cost efficiency objectives drive outsourcing models replacing capital-intensive internal manufacturing investments.
Restraints: CDMO capacity constraints and regulatory qualification challenges limit market growth and customer service capabilities.
Manufacturing capacity limitations restrict customer acquisition and revenue generation across CDMO portfolios. Regulatory qualification processes including FDA facility inspections and compliance certification extend customer onboarding timelines and create implementation risks. Technology transfer complexity creates implementation challenges and extended commercialisation timelines. Customer concentration risk limits revenue diversification as major pharmaceutical customers create material CDMO dependencies.
Competitive pricing pressure from emerging market CDMOs constrains revenue margins and investment returns. Geopolitical and tariff uncertainties affecting raw material sourcing create cost volatility and supply chain risks. Environmental and waste management regulatory requirements increase operational complexity and cost structures. Workforce talent constraints in advanced pharmaceutical manufacturing limit operational expansion.
Opportunities: Emerging market pharmaceutical growth and advanced therapy manufacturing create substantial CDMO expansion pathways.
Pharmaceutical industry growth in emerging markets including India, China, and Southeast Asia creates manufacturing capacity requirements and CDMO expansion opportunities. Advanced therapy manufacturing including antibody-drug conjugates, cell therapies, and gene therapies requires specialised CDMO infrastructure and expertise. Personalised medicine and biomarker-driven therapies create niche CDMO opportunities addressing patient-specific manufacturing requirements. Specialty topical formulations including combination therapies, sustained-release systems, and mucosal delivery platforms create formulation development services demand.
Biologics manufacturing expansion driven by monoclonal antibodies and biopharmaceutical growth creates CDMO service diversification. Digital manufacturing integration including artificial intelligence-driven formulation optimisation and blockchain supply chain traceability create competitive differentiation. Sustainability initiatives addressing waste reduction, energy efficiency, and regenerative pharmaceutical manufacturing create premium service opportunities. Contract manufacturing partnership models with pharmaceutical companies create long-term revenue visibility and strategic alignment.
Challenges: Regulatory compliance complexity and pharmaceutical industry consolidation create operational and commercial uncertainties.
Increasing regulatory standards, such as ICH guidelines for quality, and local regulations increase the need for adjustment and training. The consolidation trend within the pharmaceutical industry limits the number of diverse customers and creates an over-reliance on a few key customers. Manufacturing and technology transfer delays affect the commercialization process. Poor quality control and non-compliance lead to reputational harm and regulatory consequences for the CDMO.
Disruptions to supply chains, causing problems with sourcing raw materials, lead to operational interruptions and customer service issues. Rising costs and wage pressures in manufacturing-centric regions cause loss of competitive edge. Environmental standards and sustainability add operational complexities and capital expenditure requirements. Digital threats and cybersecurity risks pose risks to manufacturing infrastructure operations.
Trends: Advanced therapy manufacturing and digital integration reshape CDMO service portfolios and competitive positioning strategies.
The need for specialised antibody drug conjugates becomes apparent with increased emphasis on cancer treatment. The technologies used in continuous manufacturing allow for flexibility and minimal investment cost. The use of artificial intelligence ensures that formulation, process control, and quality assessment are done without human intervention. Blockchain technology allows for tracking and documentation of production in line with regulatory requirements.
The use of sustainability incorporates carbon neutral manufacturing, minimized waste and a circular economy. The use of modular manufacturing allows quick change in formulations and minimal space for machinery. Real-time process monitoring is facilitated by advanced analytics and ensures quality management and minimizes deviations. Nearshoring technology facilitates manufacture close to customer markets.
Where Are the Biggest Opportunities in the Topical Drugs CDMO Market?
- Emerging market pharmaceutical manufacturing expansion across India, China, Southeast Asia creating capacity development demand.
- Advanced therapy manufacturing including antibody-drug conjugates, cell therapies, and gene therapy formulation development services.
- Specialty topical formulations including sustained-release systems, mucosal delivery platforms, and combination therapy manufacturing.
- Biologics manufacturing service expansion driven by monoclonal antibody production and biopharmaceutical outsourcing growth.
- Digital manufacturing integration including artificial intelligence-driven formulation optimisation and process automation services.
- Sustainability-focused manufacturing operations addressing carbon neutrality and circular economy pharmaceutical production.
- Supply chain diversification services supporting pharmaceutical companies' nearshoring and geographic risk management strategies.
- Contract manufacturing partnerships providing long-term revenue visibility through exclusive supply agreements.
- Regulatory consulting and technology transfer services supporting global product commercialisation and compliance management.
- Specialty market expansion including personalised medicine, orphan drugs, and niche therapeutic applications requiring tailored manufacturing solutions.
Topical Drugs CDMO Market Segmentation Analysis
Report Attributes | Details |
Market Size in 2025 | USD 7.99 Billion |
Market Size by 2035 | USD 16.47 Billion |
CAGR (2026-2035) | 7.50% |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Historical Data | 2022-2024 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, Analysis, Forecast Outlook |
Key Segments | By Service Type: Product Development Services, Standalone Analytical and Testing Services, Clinical Manufacturing Services, Commercial Manufacturing Services, Others By Formulation:
By Product Type: Prescription Drugs, OTC Drugs By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Others |
Regional Analysis/Coverage | North America (U.S, Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, rest of Asia Pacific), LAMEA (Latin America, Middle East, and Africa) |
Company Profiles | MedPharm (U.K.), Lubrizol (U.S.), Douglas Limited (New Zealand), Piramal Pharma Solutions (India), Recipharm AB (Switzerland), Aenova Holding GmbH (Germany), CordenPharma (Switzerland), Delpharm (France), FAMAR (Greece), FAREVA (Luxembourg) |
Source: Kaiso Research and Consulting
Topical Drugs CDMO Market Segment Analysis
- By Service Type: Commercial Manufacturing Services dominated the "Topical Drugs CDMO Market Size, Share, Trends & Global Forecast 2026–2035" Market in 2025 with approximately 48% share; Product Development Services is the fastest-growing service type with a CAGR of approximately 9.2% from 2026 to 2035.
- By Formulation: Semi-solid Formulations dominated the "Topical Drugs CDMO Market Size, Share, Trends & Global Forecast 2026–2035" Market in 2025 with approximately 42.5% share; Transdermal Products is the fastest-growing formulation with a CAGR of approximately 10.1% from 2026 to 2035.
- By Product Type: Prescription Drugs dominated the "Topical Drugs CDMO Market Size, Share, Trends & Global Forecast 2026–2035" Market in 2025 with approximately 72% share; OTC Drugs is the fastest-growing product type with a CAGR of approximately 8.3% from 2026 to 2035.
- By End User: Pharmaceutical Companies dominated the "Topical Drugs CDMO Market Size, Share, Trends & Global Forecast 2026–2035" Market in 2025 with approximately 58% share; Biopharmaceutical Companies is the fastest-growing end-user segment with a CAGR of approximately 9.7% from 2026 to 2035.
Dominating Segments in the Topical Drugs CDMO Market
By Service Type: Commercial Manufacturing Services dominance reflects mature outsourcing relationships; Product Development Services accelerate through formulation complexity.
Commercial Manufacturing Services had the largest market share, contributing 48% of the total share in 2025. The high share is attributed to already existing relationships between pharmaceutical manufacturers and outsourcers, established supply agreements, and stable customer contracts. These services help to meet commercial manufacturing needs and manage existing product lines in the pharmaceutical industry. However, Product Development Services is the fastest-growing category in the industry, which will experience a CAGR of 9.2% from 2026 to 2035.
The growth is associated with the increase in complexity of the formulation process, new drug delivery systems, and regulatory changes. The use of CDMOs becomes more and more common among the pharmaceutical sector because of the need to solve formulation-related problems, optimize drug delivery, and manage the regulatory process. Furthermore, Clinical Manufacturing Services are needed in order to produce materials necessary for clinical trials. Also, Analytical Testing Services help to validate and document products.
In June 2025, Piramal Pharma Solutions announced USD 90 million investment expanding sterile injectable and topical formulation manufacturing capacity, reflecting sustained commercial manufacturing demand and strategic capacity expansion supporting accelerating biopharmaceutical outsourcing.
By Formulation: Semi-solid formulations dominate through dermatology application predominance; Transdermal products accelerate addressing pain management trends.
Semi-solids formulations constituted 42.5% of the total market share in 2025. Such formulations include creams for hydration and treatment of the skin, ointments for protection, gels that facilitate fast absorption and have an aesthetic value, and specialty vehicles for advanced therapeutic purposes. Such formulations dominate due to the large dermatology market and developed product lines for topical application. Transdermal products emerge as the leading formulation category, with the highest CAGR rate predicted at 10.1% between 2026 and 2035.
Such growth is attributed to increasing demand for pain management solutions, development of hormone replacement therapies, and advancement in patch technology. Transdermals provide patients with more convenient and comfortable ways to take their medications compared to oral dosage forms, thus ensuring increased compliance and reducing side effects of such treatments. Furthermore, liquids and solids continue being used for ophthalmology, oral cavity treatments, and specialized drug delivery. Growing need for patient-friendly administration and targeted delivery will drive market growth in such categories.
In October 2025, MedPharm announced commercial manufacturing agreement supporting specialty topical pharmaceutical product transfer, reflecting sustained semi-solid formulation manufacturing demand and market leadership in Durham facility topical production expertise.
By Product Type: Prescription Drugs dominance reflects complex formulation requirements and regulatory compliance; OTC accelerates through consumer health expansion.
Prescription Drugs held the maximum market share of 72% in the CDMO market in 2025. The high market share of this product is due to complex formulations, complicated regulatory pathways, and expertise of pharmaceutical manufacturers to outsource to CDMOs. Prescription Drugs need specialized manufacturing and drug delivery technology and advanced quality assurance to meet their needs of regulation and therapy. On the other hand, the fastest-growing product type in the CDMO market is Over-the-Counter (OTC) Drugs that are predicted to have a CAGR of 8.3% in the coming decade (2026-2035).
The reasons behind this high growth rate are consumer healthcare markets expansion, more self-medication trend among people, and strategic moves of pharmaceutical companies to increase their product portfolio in this segment. In addition, OTC manufacturing needs to comply with consumer healthcare laws and regulations, as well as quality standards and manufacturing process. Furthermore, the development of generic drugs and biosimilars is pushing CDMOs to develop their specialization in manufacturing and formulations of this kind of drugs.
In February 2025, Recipharm completed modular sterile filling system installation at Wasserburg Germany facility, supporting prescription pharmaceutical and biopharmaceutical manufacturing requirements addressing escalating complex product demands.
By End User: Pharmaceutical Companies leadership reflects market concentration; Biopharmaceutical Companies accelerate through outsourcing transformation.
Pharmaceutical Companies captured the leading position in the CDMO market in 2025 with a share of 58%. This market dominance is due to outsourcing practices, contractual arrangements, and diversified contract manufacturing portfolios. The use of CDMOs by pharmaceutical companies allows for handling of non-core manufacturing activities, improvement of production efficiency, and obtaining special knowledge without investing in production facilities. On the other hand, Biopharmaceutical Companies are seen as the fastest-growing end-users in the CDMO market. They are anticipated to generate a CAGR of 9.7% between 2026 and 2035.
Such growth is associated with venture financing for biologic drug development, advanced therapy manufacturing, and an outsourcing-based business model. The main reason why many biopharmaceutical companies have to deal with CDMOs is the absence of manufacturing infrastructure required for producing biologics. In particular, new companies within biopharmaceutical industry need manufacturing services which are flexible enough to help them to move from research and development phase to commercialisation phase.
In June 2025, Piramal Pharma Solutions strengthened biopharmaceutical customer base through USD 90 million facility investment, positioning company to capture growing outsourcing demand from expanding biopharmaceutical pipeline and advanced therapy manufacturing requirements.
Regional Insights in the Topical Drugs CDMO Market
Regional Analysis:
Region | Major Country | Share within Region, 2025 (%) |
North America | USA | 79.2 |
Europe | Germany | 31.0 |
Asia-Pacific | India | 42.0 |
Latin America | Brazil | 58.0 |
North America: Advanced healthcare infrastructure and pharmaceutical R&D investment drive North American CDMO market leadership and manufacturing capacity.
North America leads in the worldwide Topical Drugs CDMO Market and constitutes around 38.6% of the regional market share in 2025. The region is set to witness a CAGR of around 7.8% during 2026 and 2035 owing to the presence of well-established pharmaceutical outsourcing services, regulations, and advanced manufacturing capabilities. The US constitutes around 79.2% of the North American market and holds a value of approximately USD 2.44 billion in 2025 owing to pharmaceutical outsourcing, expansion of the biopharmaceutical sector, and advanced formulations.
Government regulations, tax incentives, and regulatory environment contribute to technological advancements and investment in infrastructures. Cloud-based compliance system along with automated manufacturing process speeds up the adoption of technology. Leading CDMOs like MedPharm, Lubrizol, and CordenPharma possess huge operations in the region to serve their pharmaceutical clients. Some key growth opportunities are to be found in the expansion of biopharmaceutical outsourcing, advanced drug delivery technology, and supply chain nearshoring.
In October 2025, MedPharm signed a commercial manufacturing agreement for branded specialty topical pharmaceutical product transfer to Durham facility, representing fifth major commercial deal in twenty months, reinforcing North American market leadership and facility specialisation.
USA: Biopharmaceutical outsourcing growth and formulation complexity expansion establish USA market position within North American pharmaceutical manufacturing.
The USA topicals drugs CDMO market size was approximately USD 2.44 billion in 2025 and is expected to grow up to around USD 5.17 billion by 2035, with a compound annual growth rate of about 7.9% during 2026 to 2035. The USA holds an approximate share of about 79.2% in the North American CDMO market due to pharmaceutical company concentration, focus on biopharmaceutical outsourcing and specialized formulation development.
Pharmaceutical companies, biopharmaceutical start-ups and contract manufacturers are dominant customers requiring CDMO services. Financial services, venture capital and pharmaceutical investment companies facilitate the development of the CDMO ecosystem. Increased formulation complexity and advanced delivery technologies drive the growth of demand for CDMO services. Growth opportunities include biopharmaceutical manufacturing scale-up, formulation development and supply chain risk management services. MedPharm, Lubrizol, CordenPharma and Enzyme Development Corporation are some strategic players supporting demand in the USA market.
In October 2025, MedPharm announced commercial manufacturing agreement supporting technology transfer and production of branded specialty topical pharmaceutical at Durham facility, representing fifth major commercial deal in twenty months and reinforcing USA market leadership.
Europe: Regulatory expertise and pharmaceutical formulation capability drive European CDMO market differentiation and specialisation.
Europe's topical drugs CDMO market is estimated to register CAGR of about 7.1% between 2026 and 2035 owing to the experience in manufacturing of pharmaceuticals, regulatory expertise, and advanced formulating techniques. Germany occupies a market share of approximately 31% in Europe's CDMO market due to its experience in manufacturing pharmaceutical products. Other countries demonstrating sustainable demand for the services include France, the United Kingdom, and Switzerland due to biopharmaceutical innovations and pharmaceutical outsourcing.
In terms of regional policies, compliance with regulations, quality, and manufacturing processes are given importance. The service providers in Europe such as Recipharm, Aenova, Delpharm, and FAMAR have been extending their services to cater to the needs of pharmaceutical industry. Initiatives towards sustainability involving energy-efficient manufacturing process and waste management act as competitive advantages. The key opportunities in this region include formulation of advanced therapies, increased biopharmaceutical outsourcing, and regulatory consulting.
In February 2025, Recipharm inaugurated sterile development laboratories at Bengaluru India site, establishing global manufacturing network whilst maintaining European operational excellence through advanced formulation and analytical capabilities serving regional pharmaceutical requirements.
Asia-Pacific: Pharmaceutical manufacturing growth and biopharmaceutical industry expansion establish Asia-Pacific as highest-growth CDMO region.
Asia-Pacific experiences fastest regional growth, recording a CAGR of about 9.8% between 2026 and 2035 and holds a share of around 24.1% in the global market share. India holds approximately 42% of the Asia-Pacific CDMO market share due to cost benefits in pharmaceutical manufacturing and contract manufacturing practices, as well as developments within the biopharmaceutical industry.
Japan is a sub-market characterised by specialty pharmaceutical manufacturing that takes care of complicated formulations. The government procurement efforts and policies that promote the pharmaceutical industry form the demand drivers. Regional CDMO players such as Piramal Pharma Solutions enhance their capacities to cater for the needs of the Asia-Pacific region. Innovation focuses on cost-effective formulations, customized services catering to the preferences of the regional markets, and manufacturing that can be automated. Strategic opportunities focus on outsourcing for pharmaceuticals from emerging markets, growth in biopharmaceutical manufacturing, and cost-effective formulation development.
In February 2025, Recipharm inaugurated newly commissioned sterile development and analytical testing laboratories at Bengaluru India site, expanding Asia-Pacific capabilities for advanced therapy manufacturing and supporting continued regional double-digit growth trajectories.
Japan: Advanced pharmaceutical manufacturing and specialised formulation expertise drive Japan market position within Asia-Pacific.
Japan represents about 6% of the Asia-Pacific CDMO market, and its CAGR for the period between 2026 and 2035 will be about 6.2%. The sector of contract development and manufacturing in Japan is characterized by the presence of a well-developed pharmaceutical industry, advanced technology and high quality standards. In addition, CDMOs in Japan pay more attention to specialized manufacturing services such as complex topical preparations, combination products, and products requiring exact formulation control. Such characteristics can help pharmaceutical companies that are looking for reliable partners for manufacturing.
Pharmaceutical companies in Japan tend to outsource some manufacturing functions to CDMOs so that they could focus on research, development, and commercialization. There are good opportunities for those service providers who offer innovative manufacturing and specialized pharmaceutical formulations. Innovations in the area will be associated with precision manufacturing, process improvements, and advanced pharmaceutical formulations. There is government support in the area of pharmaceutical research and development and pharmaceutical manufacturing.
Japan’s CDMO market also benefits from evolving healthcare requirements associated with its ageing population and increasing demand for advanced therapeutic products. Biopharmaceutical manufacturing represents an important area for future investment, particularly as companies seek specialised capabilities for complex biologic production and formulation development. Additional opportunities include advanced drug delivery systems, pharmaceutical product innovation, and integrated development services. Overall, market expansion reflects Japan’s technological sophistication, established pharmaceutical expertise, emphasis on manufacturing quality, and continued investment in innovative medicines.
In February 2025, Recipharm announced new pilot-scale development facility expansion complementing existing product development capabilities, positioning company for continued CDMO service leadership and supporting accelerated development timelines for clinical supply across North American and international markets.
LAMEA: Emerging market pharmaceutical growth and manufacturing cost advantages drive Latin American CDMO expansion opportunity.
The market for LAMEA topical drugs CDMO is expected to grow at a CAGR of roughly 8.1% during the forecast period of 2026-2035. Around 58% of market share is held by Brazil, due to pharmaceutical manufacturing growth, development in the biotech industry, and investment in contract manufacturing. Argentina, Mexico, and Colombia are witnessing growing use of CDMOs, owing to technology transfer and manufacturing capabilities modernization. Regional policies are becoming more supportive for investing in pharmaceutical manufacturing.
Local distributors and international CDMO suppliers are increasing their presence in Latin America in order to meet the rising demands. Innovations revolve around cost-effective manufacturing, easier formulation requirements, and solutions that address emerging markets. The key growth areas include the development of biopharmaceuticals, scaling of pharmaceutical manufacturing, and provision of cost-competitive contract manufacturing services. Market growth will be fuelled by the expansion of pharmaceutical industry, investments in the region, and geographic diversification of international CDMO network. Furthermore, market development will help in managing supply chain risks and nearshoring for pharmaceutical companies.
In June 2025, Piramal Pharma announced USD 90 million investment across US facilities, expanding sterile injectable and formulation manufacturing capabilities, positioning company for continued CDMO leadership supporting biopharmaceutical industry expansion and specialty formulation manufacturing demand.
How Can Stakeholders Benefit from the Topical Drugs CDMO Market Report?
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.

